Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYH33 + Olaparib in Advanced Solid Tumors
NCT04586335Phase 1Terminated
- Sponsor
- Haihe
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of risovalisib mesylate in solid tumor, ovarian cancer, breast cancer and 4 more, sponsored by Haihe. Primary endpoints: Dose Limiting Toxicities at 12 months and Objective Response Rate at 38 months. Started Sep 2020; status: terminated.
02
Drugs
risovalisib mesylate
03
Conditions
solid tumorovarian cancerbreast cancerprostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04586335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586335.